

AGENDA

IMI Stakeholder Forum 2013 Brussels, Belgium, 13 May 2013 Sharetan Brussels Hetal Blace Bosies 3 Brussels

2nd Floor, Sheraton Brussels Hotel, Place Rogier 3, Brussels 9:30 - 17:00

8:30 - 9:30 Registration and networking breakfast, 2nd Floor

9:30 – 9:40 Welcome and introduction

Michel Goldman, Executive Director, IMI

9:40 -10:10 **Keynote speech**

New treatments for brain disorders – needs and challenges

Richard Frackowiak, Head of Service of Neurology, CHUV University Hospital, Switzerland*

10:10 – 12:20 **IMI's neuroscience projects – pan-European public- private partnerships in brain research**

Session chair

Peter Andersen, Chair, EFPIA Research Directors Group

NEWMEDS - schizophrenia & depression

Tine Bryan Stensbøl, Divisional Director for Synaptic Transmission Research, Lundbeck

PHARMACOG - Alzheimer's disease

Esther Schenker, Research Project Leader, Institut de Recherches Servier

EUROPAIN - chronic pain

Jordi Serra, Chief Scientific Officer, Neuroscience Technologies

11:10 - 11:40 Tea/coffee break

EU-AIMS - autism

Will Spooren, Section Head, F. Hoffmann-La Roche

EMIF-AD - Alzheimer's disease

Pieter Jelle Visser, Senior Clinical Researcher, Maastricht University

12:20 – 13:00 The future of European brain research: challenges and opportunities

Session chairs

Ruxandra Draghia-Akli, Director, Health Directorate, DG Research & Innovation, European Commission

Peter Andersen, Chair, EFPIA Research Directors Group

Introductory remarks

Ruxandra Draghia-Akli

Panel discussion

Philippe Amouyel, Chair of the Executive Board, EU Joint Programme – Neurodegenerative Disease Research (JPND) **Mary Baker**, President, European Brain Council **Robert Ring**, Vice President of Translational Research, Autism Speaks



Avenue de la Toison d'Or, 1060 Brussels tel: +32 (0)2-221 81 81 - web: www.imi.europa.eu





13:00 - 14:00

Networking lunch

14:00 - 15:00 IMI in the European Research Area

Session Chair

Adam Smith, Editorial Director, Nobel Media AB

IMI – a view from the European Parliament Françoise Grossetête, MEP, European Parliament

The biopharmaceutical industry and IMI *Richard Bergström*, *Director General*, *EFPIA*

The European Commission and IMI Robert-Jan Smits, Director-General for Research and Innovation, European Commission

15: 00- 15:45 Closing keynote speech

Immunity versus Immunological Memory Rolf Zinkernagel, Professor Emeritus, University Hospital Zürich Nobel Prize for Physiology or Medicine, 1996

15:45 – 16:00 Questions and answers

16:00 – 17:00 Networking reception

Horizon Suite, 30th floor

17:00 End of meeting



tel: +32 (0)2-221 81 81 - web: <u>www.imi.europa.eu</u>